Global Hemostatic Gels Market By Product Type (Thrombin-based hemostatic gel, Gelatin-based hemostatic gel, Collagen-based hemostatic gel, Synthetic polymer–based, Others); By Application (General Surgery, Dental Surgery, Veterinary Surgery, Cardiovascular Surgery, Orthopaedic Surgery and Others); By End-User (Hospitals, Ambulatory surgical centers (ASCs), Speciality Clinics, Veterinary Settings and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

Global Hemostatic Gels Market size is expected to be worth around US$ 2.25 Billion by 2034 from US$ 1.20 Billion in 2024, growing at a CAGR of 6.5% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 36.5% share with a revenue of US$ 438.0 Million.

The Hemostatic Gels Market is emerging as a critical segment within advanced surgical wound management, driven by the rising volume of surgical procedures, trauma cases, and emergency care interventions requiring rapid and effective bleeding control. Hemostatic gels composed of thrombin, gelatin, collagen, or synthetic polymers enable immediate hemostasis by accelerating clot formation at the application site.

Hospitals, ambulatory surgical centers, trauma units, and specialty clinics rely on these formulations to reduce intraoperative bleeding, improve visualization, and enhance surgical workflow efficiency.Growing adoption across general surgery, cardiovascular interventions, orthopedic procedures, dental surgeries, and veterinary practice strengthens market expansion as healthcare systems emphasize safer, faster, and more controlled bleeding management.

Technological advancements have resulted in more biocompatible, rapidly acting, and easy-to-apply gel formulations that integrate seamlessly into surgical protocols. Manufacturers are expanding portfolios to include enzyme-enhanced gels, cross-linked polymer gels, and adjunctive combinations to deliver improved hemostatic performance.

In August 2024, Cresilon Inc., a biotechnology company headquartered in Brooklyn and specializing in hemostatic medical device technologies, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for TRAUMAGEL®, authorizing its temporary external use to manage moderate to severe bleeding. Rising surgical volume globally including elective procedures, trauma repairs, and minimally invasive surgeries continues to propel product demand across high-acuity and routine care settings.

Key Takeaways

• In 2024, the market generated a revenue of US$ 1.20 billion, with a CAGR of 6.5%, and is expected to reach US$ 2.25 billion by the year 2034.
• The Product Type segment comprises Thrombin-based, Gelatin-based, Collagen-based, Synthetic polymer–based gels, and Others, with thrombin-based gels dominating with 34.7% market share in 2024 due to fast clot activation.
• The Application segment includes General Surgery, Dental Surgery, Veterinary Surgery, Cardiovascular Surgery, Orthopedic Surgery, and Others, with General Surgery accounting for the highest share in 2024 of 40.5%.
• The End-User segment covers Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Veterinary Settings, and Others, with hospitals leading due to high-volume procedures with 52.3% market share in 2024.
• North America led the market by securing a market share of 36.5% in 2024.

Product Type Analysis

Thrombin-based hemostatic gels dominated the market in 2024 with 34.7% market share because of their ability to rapidly convert fibrinogen into fibrin, enabling quick clot formation during open and minimally invasive surgeries. Surgeons rely heavily on thrombin-enriched formulations during general, cardiovascular, and orthopedic procedures where precision bleeding control is essential. Additionally, these products integrate effectively with absorbable dressings and surgical sponges, improving their clinical applicability.

Gelatin-based gels continue to gain traction due to high absorbency and mechanical tamponade effects, often preferred in ENT, dental, and orthopedic procedures. Collagen-based gels deliver strong clot adherence and are valued for high biocompatibility, particularly in reconstructive and dental surgeries. Synthetic polymer–based gels support controlled degradation, easy application, and consistent viscosity, making them popular in minimally invasive surgeries.

Application Analysis

General Surgery accounted for the largest share in 2024 of 40.5% as these procedures frequently require immediate hemostasis to maintain visualization and reduce operative time. Hemostatic gels are widely utilized in laparoscopic surgeries, tumor resections, abdominal repairs, and trauma management.

Dental Surgery represents a rapidly expanding segment due to rising implantology, periodontal procedures, and oral reconstructive surgeries where gels help stabilize clots and reduce postoperative bleeding. Orthopedic Surgery shows substantial application in joint replacements, fracture repairs, and spinal procedures, where reducing intraoperative blood loss is critical.

Cardiovascular Surgery, involving high-risk bleeding environments, also heavily relies on fast-acting gels. Veterinary Surgery is expanding steadily with increasing surgical care for companion animals and livestock; gels help manage both soft-tissue and orthopedic cases.

End-User Analysis

Hospitals held the largest end-user share in 2024 accounting for over 52.3% market share due to high surgical loads, trauma admissions, and access to advanced hemostatic technologies. Operating rooms, emergency departments, and intensive care units depend on hemostatic gels for rapid bleeding control across multiple surgical specialties.

Ambulatory Surgical Centers (ASCs) increasingly adopt hemostatic gels due to a rise in day-care surgeries including orthopedic arthroscopy, ENT procedures, and dental implants. Specialty clinics such as dental clinics, orthopedic centers, and dermatologic surgery units utilize gels for minimally invasive procedures and postoperative bleeding control. Veterinary Settings show consistent adoption supported by rising animal healthcare spending. The “Others” category includes military medical units, field hospitals, and remote surgical settings using portable hemostatic solutions.

Key Market Segments

By Product Type

• Thrombin-based hemostatic gel
• Gelatin-based hemostatic gel
• Collagen-based hemostatic gel
• Synthetic polymer–based
• Others

By Application

• General Surgery
• Dental Surgery
• Veterinary Surgery
• Cardiovascular Surgery
• Orthopaedic Surgery
• Others

By End-User

• Hospitals
• Ambulatory surgical centers (ASCs)
• Speciality Clinics
• Veterinary Settings
• Others

Drivers

Rising Surgical Volume and Global Need for Rapid, Reliable Bleeding Control

The Hemostatic Gels Market is driven primarily by the surge in global surgical procedures and the rising need for rapid, reliable intraoperative bleeding management. According to the World Health Organization, more than 310 million major surgeries are performed annually worldwide, with nearly 40–50 million in the US and Europe and over 20 million in India alone.

As surgical loads rise across general surgery, cardiovascular interventions, orthopedics, dental implants, spinal repairs, and trauma procedures, surgeons increasingly rely on hemostatic gels to reduce blood loss, shorten operative times, and minimize transfusion dependency. Trauma and accident-related surgeries also contribute significantly, with the Global Road Safety Report estimating 1.19 million annual road-traffic deaths and tens of millions of injuries requiring emergency surgical care.

Hemostatic gels are particularly important in minimally invasive and robotic-assisted procedures, where bleeding obstructs visibility and prolongs surgical time. For example, orthopaedic surgeries such as the 1.3 million annual hip and knee replacements performed in the US (AAOS data) commonly require topical hemostats to control bone-surface bleeding. Cardiac surgeries rely heavily on thrombin- and collagen-based gels to manage diffuse bleeding around graft and anastomotic sites. With aging populations expanding—projected by the UN to reach 1.6 billion people aged 65+ by 2050 surgery volumes and bleeding-management needs continue to escalate, fueling market demand.

Restraints

High Cost, Variable Access, and Inconsistent Adoption Across Healthcare Systems

Despite strong clinical benefits, the Hemostatic Gels Market faces restraints stemming from high product cost, limited reimbursement, and variable accessibility in low- and middle-income regions. Advanced thrombin- and collagen-based gels are considerably more expensive than traditional options such as pressure dressings, cautery, or gauze pads. Hospitals in emerging economies face budget constraints that limit routine adoption, with expenditure on surgical consumables already accounting for 15–25% of total operative care costs in many public systems.

Additionally, the need for highly purified thrombin sources or bovine/porcine-derived collagen raises manufacturing expenses and supply-chain vulnerability. Regulatory approvals for biologically derived materials often increase time-to-market and compliance costs, affecting pricing downstream. Small clinics, dental facilities, and rural hospitals frequently opt for cheaper hemostatic agents such as oxidized cellulose or simple gelatin sponges reducing market penetration of gels.

Clinical variability also acts as a restraint. The performance of hemostatic gels is influenced by patient comorbidities, anticoagulant therapy, and type of surgical field. Surgeons may hesitate to switch from familiar hemostatic tools due to training gaps or concerns about interactions with tissue adhesives and sutures.

Opportunities

Growth of Minimally Invasive Surgeries and Next-Generation Gel Technologies

The strongest opportunity for the Hemostatic Gels Market lies in the rapid expansion of minimally invasive procedures (laparoscopy, arthroscopy, robotic surgery) and the development of next-generation bioengineered hemostatic gels. Globally, minimally invasive surgeries now represent over 35% of all elective surgical procedures, according to OECD clinical data, and are growing at double-digit rates in Asia Pacific and Latin America. These procedures demand precise, fast-acting gels deliverable through small trocars, flexible catheters, or laparoscopic ports. Synthetic polymer–based gels with controlled viscosity and enhanced adherence address this need effectively, creating strong commercial potential.

Next-generation formulations such as enzyme-accelerated gels, recombinant thrombin gels, plant-derived collagen gels, and antimicrobial gel composites further widen application potential. For example, recombinant thrombin reduces risk of immune reactions associated with bovine-derived thrombin, creating growing demand in North America and Europe. In May 2025, Baxter launches HEMOPATCH Sealing Hemostat, a room-temperature collagen pad. Baxter introduced a room-temperature stable collagen-based hemostat (suitable for open and minimally invasive surgery), expanding its tissue-management product portfolio.

The veterinary surgery market presents another high-growth opportunity, with the American Veterinary Medical Association reporting over 4.4 million surgical procedures performed annually in companion animals in the US alone. Dental implantology performing over 12 million implants per year globally relies increasingly on localized hemostatic support, expanding demand for user-friendly syringe-based gels.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical conditions have been observed to influence the Hemostatic Gels Market by shaping purchasing behavior, supply chain resilience, and access to essential production inputs. Periods of economic deceleration generally redirect household spending toward core healthcare needs, and this trend supports the uptake of cost-efficient at-home diagnostic solutions, as these are perceived as lower-cost substitutes to clinical testing.

At the same time, inflationary pressures on raw materials and transportation have been associated with higher production and distribution costs, which can translate into elevated retail prices in cost-sensitive regions. Geopolitical frictions further affect the availability of assay components, microfluidic elements, reagents, and lateral-flow materials, many of which are sourced from diversified international manufacturing hubs. Any disruption to global trade routes or export regulations for critical chemicals tends to prolong production lead times and constrain inventory levels across online and brick-and-mortar channels.

Public health policy adjustments resulting from geopolitical instability also contribute to shifting demand patterns. Heightened uncertainty surrounding global energy and food supplies has increased consumer attention to immunity, fatigue, and nutritional status, thereby supporting greater engagement in self-monitoring practices. Changes in labor markets, particularly the expansion of remote work, have reinforced the preference for home-based diagnostic options over traditional clinical visits. Concurrently, stricter government oversight of cross-border data flows and digital health privacy is expected to influence how diagnostic providers manage, store, and protect user information.

Latest Trends

Bioengineered Hemostatic Gels, Sustainability Focus, and Rapid Adoption in Robotics

A major trend shaping the Hemostatic Gels Market is the shift toward bioengineered, more biocompatible, and environmentally sustainable gel formulations. New-generation hemostatic gels increasingly use plant-derived collagen, recombinant enzymes, biodegradable polymers, and cross-linked biopolymers that improve clot stability while reducing reliance on animal-derived components. This shift aligns with rising regulatory pressure and global sustainability goals. Additionally, antimicrobial-enriched hemostatic gels are gaining momentum as surgical-site infections remain a major complication, with the CDC reporting 2,70,000+ surgical infections annually in the US.

Growth in robotic-assisted surgeries also drives demand for gels optimized for narrow surgical fields. According to the International Federation of Robotics, over 1.2 million robotic surgeries were performed worldwide in 2024 a number growing significantly each year. These procedures require highly flow-controlled gels that can be precisely delivered through robotic arms under digital visualization.

Regional Analysis

North America is leading the Hemostatic Gels Market

North America dominated the market in 2024 with covering 36.5% market share due to its advanced surgical care systems, high trauma incidence, and strong adoption of innovative wound-management technologies. Large hospitals and trauma centers use hemostatic gels extensively in general, orthopedic, cardiovascular, and dental surgeries. Strong presence of leading manufacturers and active product development enhances market penetration.

High healthcare spending, well-defined reimbursement policies, and a surge in outpatient surgery center expansions contribute to regional leadership. LifeGel™ is described as a ready-to-use, flowable hemostatic gel that coats bleeding sites without swelling addressing risks in confined surgical spaces like spinal surgery, where swelling may cause complications.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

Asia Pacific is expected to grow at the highest CAGR through 2034 due to rising surgical procedure volumes in China, India, South Korea, and Southeast Asia. Increasing road accident rates, a growing geriatric population, and rapid expansion of private hospitals strengthen market adoption. Public healthcare investments, medical tourism growth, and rising dental surgery volumes accelerate the use of hemostatic gels. Local manufacturers introduce cost-effective formulations, improving accessibility across emerging markets.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

Key players in the market include Baxter International Inc., Ethicon, Inc. (Johnson & Johnson), Pfizer, Inc., B. Braun SE, Becton, Dickinson and Company (BD), Integra LifeSciences Corporation, CryoLife, Inc., Cresilon, Inc., Aegis Lifesciences, Advanced Medical Solutions Group plc, Other key players

Baxter International Inc. develops hemostatic gel solutions integrated into its surgical care portfolio, emphasizing rapid bleeding control and improved operative efficiency. The company leverages its global distribution and strong clinical adoption to expand access to advanced topical hemostats across complex and routine surgical settings.

Ethicon, Inc. (Johnson & Johnson) offers a broad range of hemostatic gels designed to enhance intraoperative bleeding management, combining biomaterial innovation with strong surgeon-focused R&D. Its comprehensive surgical ecosystem supports widespread adoption across specialties, reinforcing its position in advanced wound and tissue management.

Pfizer integrates hemostatic technologies within its diversified healthcare portfolio, focusing on biologically engineered solutions that aid effective bleeding control in surgical procedures. Strong manufacturing capabilities, clinical research, and strategic collaborations support its presence in the expanding hemostatic gels segment.

Top Key Players

• Baxter International Inc.
• Ethicon, Inc. (Johnson & Johnson)
• Pfizer, Inc.
• Braun SE
• Becton, Dickinson and Company (BD)
• Integra LifeSciences Corporation
• CryoLife, Inc.
• Cresilon, Inc.
• Aegis Lifesciences
• Advanced Medical Solutions Group plc
• Other key players

Recent Developments

• In July 2025, as part of its surgical solutions, Aegis emphasized improved haemostatic support in liver procedures, signalling growing interest in gel / matrix-based agents for complex organ surgeries.
• In June 2023, Cresilon received 510(k) clearance from U.S. Food and Drug Administration (FDA) for its plant-based Hemostatic Gel (“CHG™”), allowing local management of bleeding wounds like cuts, lacerations, abrasions.
• In November 2022, Cresilon introduced an advanced hemostatic gel designed for treating wounds in animals. Backed by $25 million in Series A funding, the company has been progressing efforts to adapt this life-saving technology for human medical use. 

Report Scope